North Dakota State Investment Board Purchases Shares of 43,981 Medtronic PLC $MDT

North Dakota State Investment Board purchased a new stake in Medtronic PLC (NYSE:MDT) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 43,981 shares of the medical technology company’s stock, valued at approximately $4,225,000.

A number of other institutional investors have also recently made changes to their positions in MDT. Brighton Jones LLC lifted its stake in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after purchasing an additional 381 shares during the period. Jump Financial LLC acquired a new position in shares of Medtronic in the 2nd quarter valued at about $299,000. Main Street Financial Solutions LLC lifted its stake in shares of Medtronic by 28.9% in the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after purchasing an additional 3,218 shares during the period. Finally, HUB Investment Partners LLC lifted its stake in shares of Medtronic by 21.3% in the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock valued at $1,676,000 after purchasing an additional 3,376 shares during the period. Institutional investors own 82.06% of the company’s stock.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.26% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

MDT has been the topic of a number of recent analyst reports. Stifel Nicolaus dropped their price objective on Medtronic from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Monday, April 6th. Weiss Ratings downgraded Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, April 21st. Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. Argus dropped their price objective on Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Finally, Wells Fargo & Company initiated coverage on Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 price objective on the stock. Fifteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $107.80.

Medtronic Stock Performance

Shares of Medtronic stock opened at $76.12 on Monday. The company has a market cap of $97.73 billion, a PE ratio of 21.20, a price-to-earnings-growth ratio of 1.81 and a beta of 0.62. Medtronic PLC has a 52 week low of $74.40 and a 52 week high of $106.33. The business has a 50 day moving average price of $84.76 and a 200-day moving average price of $93.63. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts anticipate that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.7%. Medtronic’s dividend payout ratio is 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).